Arrestin-selective biased AT1 agonists negatively modulate B2 receptor signaling by internalizing AT1-B2 heterodimers, suggesting distinct pharmacological actions compared to neutral AT1 antagonists.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for biased AT1 agonism modulating B2 via heterodimers in animals; leaves open human relevance and clinical translation.
The renin-angiotensin and kallikrein-kinin systems are key regulators of vascular tone and inflammation. Angiotensin II, the principal effector of the renin-angiotensin system, promotes vasoconstriction by activating angiotensin AT 1 receptors. The opposing effects of the kallikrein-kinin system are mediated by bradykinin acting on B 1 and B 2 bradykinin receptors. The renin-angiotensin and kallikrein-kinin systems engage in cross-talk at multiple levels, including the formation of AT 1 -B 2 receptor heterodimers. In primary vascular smooth muscle cells, we find that the arrestin pathway-selective AT 1 agonist, [Sar 1 ,Ile 4 ,Ile 8 ]-AngII, but not the neutral AT 1 antagonist, losartan, inhibits endogenous B 2 receptor signaling. In a transfected HEK293 cell model that recapitulates this effect, we find that the actions of [Sar 1 ,Ile 4 , Ile 8 ]-AngII require the AT 1 receptor and result from arrestin-dependent co-internalization of AT 1 -B 2 heterodimers. BRET 50 measurements indicate that AT 1 and B 2 receptors efficiently heterodimerize. In cells expressing both receptors, pretreatment with [Sar 1 ,Ile 4 ,Ile 8 ]-AngII blunts B 2 receptor activation of G q/11 -dependent intracellular calcium influx and G i/o -dependent inhibition of adenylyl cyclase. In contrast, [Sar 1 ,Ile 4 ,Ile 8 ]-AngII has no effect on B 2 receptor ligand affinity or bradykinin-induced arrestin3 recruitment. Both radioligand binding assays and quantitative microscopy-based analysis demonstrate that [Sar 1 ,Ile 4 ,Ile 8 ]-AngII promotes internalization of AT 1 -B 2 heterodimers. Thus, [Sar 1 ,Ile 4 ,Ile 8 ]-AngII exerts lateral allosteric modulation of B 2 receptor signaling by binding to the orthosteric ligand binding site of the AT 1 receptor and promoting co-sequestration of AT 1 -B 2 heterodimers. Given the opposing roles of the renin-angiotensin and kallikrein-kinin systems in vivo , the distinct properties of arrestin pathway-selective and neutral AT 1 receptor ligands may translate into different pharmacologic actions. Background: Hemodynamic regulation involves extensive cross-talk between the renin-angiotensin and kallikrein-kinin systems. Results: In vascular smooth muscle, "biased" AT 1 agonists inhibit both AT 1 and B 2 signaling by internalizing AT 1 -B 2 heterodimers. Conclusion: AT 1 antagonists and arrestin-selective biased AT 1 agonists have opposing effects on B 2 signaling. Significance: Negative allosteric modulation of B 2 signaling by biased AT 1 agonists may impact their clinical utility.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: